MARKET

FLDM

FLDM

Fluidigm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.340
-0.410
-8.63%
Pre Market: 4.320 -0.02 -0.46% 04:22 03/03 EST
OPEN
4.810
PREV CLOSE
4.750
HIGH
4.950
LOW
4.340
VOLUME
250
TURNOVER
--
52 WEEK HIGH
12.45
52 WEEK LOW
1.170
MARKET CAP
323.53M
P/E (TTM)
-5.8983
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Microfluidics Market Hit $32.97 Bn in Market Cap by Year-End 2027
Mar 02, 2021 (Market Insight Reports) -- The global Microfluidics market is anticipated to grow with a significant CAGR of 11.5% during the forecast period...
Market Insight Reports · 1d ago
Single-cell Analysis Market Research, Growth Opportunities, Key Players, Outlook and Forecasts Report 2021-2025
Mar 02, 2021 (The Expresswire) -- The report presents a detailed study of “Single-cell Analysis Market” covering both global and regional markets. It aims to...
The Express Wire · 1d ago
Asia Pacific Single-cell Analysis Market worth $1,375 million by 2025 | Key Players are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US)
Mar 01, 2021 (AB Digital via COMTEX) -- According to the new market research report "Asia Pacific Single-cell Analysis Market by Cell Type (Human,...
ABNewswire · 1d ago
Fluidigm Gets EUA Nod For Home Sample Collection Kit For Advanta COVID-19 Assay
The FDA has granted Emergency Use (EUA) approval for Fluidigm Corporation's (NASDAQ: FLDM) AZOVA COVID-19 test collection kit
Benzinga · 1d ago
BRIEF-FDA Grants Emergency Use Authorization For Home Collection Kit For Advanta Dx Sars-Cov-2 Rt-Pcr Assay
reuters.com · 1d ago
Fluidigm shares rise 17% on emergency use nod in U.S. for Advanta SARS-CoV test
The FDA grants Emergency Use Authorization to Fluidigm's (FLDM) AZOVA COVID-19 Test Collection Kit for use with the Fluidigm Advanta Dx SARS-CoV-2 RT-PCR Assay on the company’s Biomark HD platform.The
Seekingalpha · 1d ago
DJ Avadel Pharma ADRs Rise Premarket After FDA Accepts NDA for FT218
Dow Jones · 1d ago
FDA GrantsEmergency Use Authorization For AZOVA COVID-19 Test Collection Kit Home Collection Kit For Usw With Fluidigm Advanta Dx SARS-CoV-2 RT-PCR Assay
Collaboration Agreement to Market AZOVA COVID-19 Test Collection Kit Online AZOVA Digital Health Platform Provides Patient Questionnaire, Process for Prescription, Kit Purchase, Sample Collection, and Secure
Benzinga · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FLDM. Analyze the recent business situations of Fluidigm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FLDM stock price target is 10.33 with a high estimate of 14.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 233
Institutional Holdings: 68.29M
% Owned: 91.60%
Shares Outstanding: 74.55M
TypeInstitutionsShares
Increased
54
8.80M
New
64
-2.77M
Decreased
33
7.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.55%
Healthcare Equipment & Supplies
-0.56%
Key Executives
Chairman/Independent Director
Carlos Paya
President/Chief Executive Officer/Director
Stephen Linthwaite
Chief Financial Officer
Vikram Jog
Senior Vice President/General Counsel/Secretary
Nicholas Khadder
Senior Vice President
Bradley Kreger
Senior Vice President
Brad Kreger
Other
Colin McCracken
Director
Ana Stankovic
Independent Director
Nicolas Barthelemy
Independent Director
Gerhard Burbach
Independent Director
Laura Clague
Independent Director
Bill Colston
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About FLDM
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

Webull offers kinds of Fluidigm Corporation stock information, including NASDAQ:FLDM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLDM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLDM stock methods without spending real money on the virtual paper trading platform.